Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC

J Thorac Oncol. 2019 Mar;14(3):e49-e50. doi: 10.1016/j.jtho.2018.11.014.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Colitis, Ischemic / chemically induced
  • Colitis, Ischemic / pathology*
  • Colitis, Ischemic / therapy
  • Fatal Outcome
  • Gastrointestinal Agents / administration & dosage
  • Humans
  • Infliximab / administration & dosage*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Nivolumab / adverse effects*
  • Prognosis

Substances

  • Antineoplastic Agents, Immunological
  • Gastrointestinal Agents
  • Nivolumab
  • Infliximab